Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Combined Ultrasound Hepatic and Renal Denervation for Essential Hypertension (uHRDN)

11 novembre 2026 mis à jour par: Shanghai Hantong Medical Technology Co., LTD

Safety, Efficacy, and Clinical Feasibility of an Ultrasound Denervation System in Subjects With Essential Hypertension: A Prospective, Multicenter, Open-Label, Single-Arm, Exploratory Study

This study will evaluate the safety and feasibility of a procedure that uses ultrasound energy to treat nerves around the arteries that supply the kidneys and liver. It will also assess whether blood pressure changes after the procedure in people whose high blood pressure remains inadequately controlled despite medication.

All participants who qualify will receive the study procedure. The study team will check for major safety events during the procedure and through 30 days afterward. The team will also compare the average systolic blood pressure measured over 24 hours before the procedure and at the 6-month follow-up.

The study will also look at changes in blood pressure medications and, for participants with type 2 diabetes, changes in blood sugar control.

Aperçu de l'étude

Statut

Pas encore de recrutement

Description détaillée

This is a prospective, multicenter, open-label, single-arm exploratory study with a planned enrollment of 10 participants. The study includes participants with essential hypertension that remains inadequately controlled after at least 4 weeks of fixed-dose combination antihypertensive therapy. Participants may have hypertension with or without type 2 diabetes.

Before the procedure, computed tomography angiography or magnetic resonance angiography is used to assess vascular anatomy. Digital subtraction angiography is used during the procedure to confirm anatomical suitability. The investigational system consists of a single-use ultrasound ablation catheter and an ultrasound ablation generator. Treatment targets the main renal arteries and the main trunk of the common hepatic artery. First-order renal artery branches may also be treated if their anatomy meets the device requirements.

The study will summarize safety, blood pressure changes, and procedural feasibility descriptively. Measures of glucose metabolism will be explored in participants with type 2 diabetes.

Type d'étude

Interventionnel

Inscription (Estimé)

10

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 75 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Age 18 to 75 years, inclusive.

  2. Diagnosed with essential hypertension and inadequately controlled blood pressure, with or without type 2 diabetes mellitus (T2DM).

  3. After providing informed consent and after the investigator confirms that switching therapy is safe, participants must take study-supplied amlodipine 5 mg/day and irbesartan 150 mg/day. After at least 28 days of standardized therapy, office systolic blood pressure must be at least 150 mmHg and less than 180 mmHg, and mean 24-hour ambulatory systolic blood pressure must be at least 135 mmHg and less than 170 mmHg, as confirmed by ambulatory blood pressure monitoring.

  4. Participants with T2DM must meet all of the following:

    • Body mass index of at least 24 kg/m².
    • HbA1c of 7.0% to 9.0% at screening or within the preceding 3 months, and again on preprocedural retesting at Visit 3.
    • No changes in the types or doses of glucose-lowering medications for at least 4 weeks before Visit 3. In principle, the regimen should remain stable until completion of the 6-month primary endpoint assessment.

Exclusion Criteria:

  1. Anatomy of either main renal artery or the main trunk of the common hepatic artery unsuitable for study treatment. Unsuitability of first-order renal artery branches for additional treatment is permitted.

  2. Any of the following on preprocedural computed tomography angiography, magnetic resonance angiography, or renal angiography:

    • Greater than 50% diameter stenosis in either main renal artery or the common hepatic artery.
    • Diameter less than 3 mm or greater than 8 mm in either main renal artery or the common hepatic artery.
  3. Previous renal artery denervation or hepatic artery denervation.

  4. History of New York Heart Association (NYHA) class III or IV heart failure within 6 months before screening.

  5. Stroke or transient ischemic attack within 6 months before screening, or any prior stroke resulting in permanent disability.

  6. Type 1 diabetes mellitus, or insulin use within 6 months before screening in participants with T2DM.

  7. Secondary hypertension.

  8. Estimated glomerular filtration rate below 40 mL/min/1.73 m², calculated using the 2021 CKD-EPI creatinine equation.

  9. Pregnancy, breastfeeding, or planned pregnancy during the study.

  10. Severe concomitant respiratory disease requiring long-term oxygen therapy or mechanical ventilation.

  11. History or evidence of active or suspected chronic liver or biliary tract disease.

  12. Current or previous chronic pancreatitis.

  13. Active severe infection, a marked bleeding tendency, or inability to receive perioperative anticoagulant or antiplatelet therapy.

  14. Any other condition that, in the investigator's judgment, precludes participation in the study.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Combined Ultrasound Hepatic and Renal Denervation

All enrolled participants receive combined ultrasound hepatic and renal denervation using the investigational ultrasound denervation system.

The investigational system consists of a single-use ultrasound ablation catheter (model HR35-1050) and an ultrasound ablation generator (model U10-HR). The system delivers ultrasound energy for denervation along the main renal arteries and the main trunk of the common hepatic artery. First-order renal artery branches may also be treated if their anatomy meets the device requirements.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change From Baseline in Mean 24-Hour Ambulatory Systolic Blood Pressure
Délai: Baseline (Visit 2) and 6 months after the procedure

Change in mean 24-hour systolic blood pressure, measured by ambulatory blood pressure monitoring and reported in mmHg. Change is calculated as the 6-month value minus the baseline (Visit 2) value.

Baseline (Visit 2) and 6 months after the procedure
Incidence of the composite endpoint of major safety events within 30 days after the procedure.
Délai: From vascular puncture at the start of the procedure through postprocedure Day 30, inclusive

Percentage of participants with at least one prespecified event: all-cause death, access-site complications requiring transfusion or invasive intervention or causing or prolonging hospitalization, target artery complications requiring intervention, new myocardial infarction, stroke, transient ischemic attack or other fatal, life-threatening or hospitalization-requiring cardiovascular or cerebrovascular events, acute kidney injury requiring dialysis or other serious renal events causing or prolonging hospitalization, acute liver failure or serious liver injury causing or prolonging hospitalization, acute pancreatitis, biliary tract or gallbladder complications requiring hospitalization or intervention, or other serious adverse events related to the device or procedure. Event relatedness to the device and to the procedure is assessed separately.

From vascular puncture at the start of the procedure through postprocedure Day 30, inclusive

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change From Baseline in Office Systolic Blood Pressure
Délai: Baseline (Visit 2) and 6 months after the procedure

Change in office systolic blood pressure, reported in mmHg, calculated as the 6-month value minus the baseline (Visit 2) value.

Baseline (Visit 2) and 6 months after the procedure
Change From Baseline in Office Diastolic Blood Pressure
Délai: Baseline (Visit 2) and 6 months after the procedure

Change in office diastolic blood pressure, reported in mmHg, calculated as the 6-month value minus the Visit 2 value.

Baseline (Visit 2) and 6 months after the procedure
Change From Baseline in Mean 24-Hour Ambulatory Diastolic Blood Pressure
Délai: Baseline (Visit 2) and 6 months after the procedure

Change in mean 24-hour diastolic blood pressure measured by ambulatory blood pressure monitoring (ABPM), reported in mmHg.

Baseline (Visit 2) and 6 months after the procedure
Change From Baseline in Mean Daytime Ambulatory Systolic Blood Pressure
Délai: Baseline (Visit 2) and 6 months after the procedure

Change in mean daytime systolic blood pressure measured by ABPM, reported in mmHg.

Baseline (Visit 2) and 6 months after the procedure
Change From Baseline in Mean Daytime Ambulatory Diastolic Blood Pressure
Délai: Baseline (Visit 2) and 6 months after the procedure

Change in mean daytime diastolic blood pressure measured by ABPM, reported in mmHg.

Baseline (Visit 2) and 6 months after the procedure
Change From Baseline in Mean Nighttime Ambulatory Systolic Blood Pressure
Délai: Baseline (Visit 2) and 6 months after the procedure

Change in mean nighttime systolic blood pressure measured by ABPM, reported in mmHg.

Baseline (Visit 2) and 6 months after the procedure
Change From Baseline in Mean Nighttime Ambulatory Diastolic Blood Pressure
Délai: Baseline (Visit 2) and 6 months after the procedure

Change in mean nighttime diastolic blood pressure measured by ABPM, reported in mmHg.

Baseline (Visit 2) and 6 months after the procedure
Proportion of Participants With Controlled Office Systolic Blood Pressure
Délai: 6 months after the procedure

Percentage of participants with office systolic blood pressure below 140 mmHg at 6 months.

6 months after the procedure
Change From Baseline in the Composite Antihypertensive Medication Index
Délai: Baseline (Visit 2) and 6 months after the procedure

Change in the protocol-defined composite antihypertensive medication index from Visit 2 to 6 months.

Baseline (Visit 2) and 6 months after the procedure
Change From Baseline in Glycated Hemoglobin in Participants With Type 2 Diabetes
Délai: Baseline (Visit 3) and 6 months after the procedure

Change in glycated hemoglobin (HbA1c), reported in percentage points, in participants with concomitant type 2 diabetes.

Baseline (Visit 3) and 6 months after the procedure
Change From Baseline in Fasting Plasma Glucose in Participants With Type 2 Diabetes
Délai: Baseline (Visit 3) and 6 months after the procedure

Change in fasting plasma glucose in participants with concomitant type 2 diabetes.

Baseline (Visit 3) and 6 months after the procedure
Changes in Glucose-Lowering Medication Use in Participants With Type 2 Diabetes
Délai: Baseline (Visit 3) and 6 months after the procedure

Changes in the types and doses of glucose-lowering medications in participants with concomitant type 2 diabetes.

Baseline (Visit 3) and 6 months after the procedure
Device Success Rate
Délai: During the procedure through device withdrawal

Percentage of participants with successful device delivery, completion of planned energy delivery, and safe device withdrawal, without a device malfunction that prevents treatment completion.

During the procedure through device withdrawal
Procedural Success Rate
Délai: During the procedure through procedure completion

Percentage of participants in whom the intended ablation is completed at anatomically appropriate sites, including at least two sites in total across both kidneys and at least one site in the common hepatic artery, with the intended procedural objective achieved and no serious intraprocedural complications.

During the procedure through procedure completion
Incidence of New Target Artery Stenosis or Vascular Lesions Requiring Intervention
Délai: 6 months after the procedure

Percentage of participants with new diameter stenosis greater than 70% in a main renal artery, a treated first-order renal artery branch, or the main trunk of the common hepatic artery, or with a relevant vascular lesion requiring intervention. Assessed by computed tomography angiography, magnetic resonance angiography, or digital subtraction angiography if needed.

6 months after the procedure
Proportion of Participants With at Least a 30% Decline in Estimated Glomerular Filtration Rate
Délai: Baseline and 6 months after the procedure, with repeat testing within 7 days of a qualifying result

Percentage of participants with a decline of at least 30% in estimated glomerular filtration rate from baseline. The first qualifying result is confirmed by repeat testing within 7 days, after excluding clearly reversible causes.

Baseline and 6 months after the procedure, with repeat testing within 7 days of a qualifying result
Changes From Baseline in Hepatobiliary Laboratory Parameters
Délai: Baseline (Visit 3) and 6 months after the procedure

Changes in alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transferase, total bilirubin, and direct bilirubin.

Baseline (Visit 3) and 6 months after the procedure
Incidence of Hepatobiliary Complications
Délai: Assessed at 6 months after the procedure

Incidence of acute liver injury, biliary stricture or obstruction, acute cholecystitis, and other hepatobiliary complications requiring hospitalization or clinical intervention.

Assessed at 6 months after the procedure
Changes From Baseline in Amylase and Lipase
Délai: Baseline and 6 months after the procedure

Changes in amylase and lipase from baseline to 6 months.

Baseline and 6 months after the procedure
Incidence of Adverse Events Through 6 Months
Délai: From the start of the procedure through 6 months

Percentage of participants with at least one adverse event.

From the start of the procedure through 6 months
Incidence of Serious Adverse Events Through 6 Months
Délai: From the start of the procedure through 6 months

Percentage of participants with at least one serious adverse event.

From the start of the procedure through 6 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Junbo Ge, hongshan Hospital, Fudan University

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

30 novembre 2026

Achèvement primaire (Estimé)

30 décembre 2027

Achèvement de l'étude (Estimé)

30 mars 2028

Dates d'inscription aux études

Première soumission

11 novembre 2026

Première soumission répondant aux critères de contrôle qualité

11 novembre 2026

Première publication (Réel)

17 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

11 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

The sponsor does not plan to share individual participant data (IPD) from this study with other researchers.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner